These trials completed more than 12 months ago and should have reported results.
These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.
These trials have problematic data on the registry. Details why »
|Status||Trial ID||Title||Completion date||Category|
|Exempt||2008-005048-17||A Combined Clinical Phase I/IIa Study of the Safety and Efficacy of Nebulised RPL554 in Healthy Subjects, Allergic Asthmatics, and Allergic Rhinitics||not-yet-due|
|Exempt||2010-021349-36||Randomised, Double-Blind, Placebo-Controlled Evaluation of the Safety and Duration of Action of 2 Single Inhaled Doses, 0.036 mg/kg (12X) and 0.072 mg/kg (24X), of RPL554, a Dual PDE 3/4 Inhibitor, in...||not-yet-due|
|Exempt||2011-001698-22||EVALUATION OF THE EFFICACY AND SAFETY OF 6 REPEATED DAILY DOSES OF NEBULISED RPL554 0.018 mg/kg (6X) IN ALLERGIC ASTHMATICS||not-yet-due|
|Other||2012-005794-31||A randomised, double-blind, placebo-controlled crossover study to assess the efficacy of a single dose of 100mg of VRP700 by inhalation in reducing the frequency and severity of cough in adult patient...||not-yet-due|
|Listed as ongoing, but also has a completion date and reported results||2014-005615-17||A Phase II, randomised, double blind, placebo controlled, seven way crossover study to assess the effect of single doses of RPL554 compared to salbutamol and placebo administered by nebuliser on lung ...||2015-11-17||bad-data|
|Reported results||2015-002536-41||A phase II, randomised, double blind, placebo controlled, six way crossover study to assess the bronchodilator effect of RPL554 administered on top of salbutamol and ipratropium in patients with COPD||2015-12-17||due-trials|
|Reported results||2015-004263-36||A Phase IIa, randomised, double blind, placebo controlled, three way crossover study to assess the pharmacokinetics of RPL554 administered to adult patients with Cystic Fibrosis.||2017-11-03||due-trials|
|Reported results||2016-004450-15||A phase II, randomised, double blind, placebo controlled, three way crossover study to assess the bronchodilator effect of RPL554 administered in addition to open label tiotropium in patients with COP...||2017-07-24||due-trials|
|Reported results||2016-005205-40||A Phase IIb, randomized, double blind, placebo controlled, dose ranging study to assess the effect of RPL554 in patients with moderate to severe COPD.||2018-02-15||due-trials|
|Reported results||2018-001037-41||A PHASE II, RANDOMISED, DOUBLE BLIND, PLACEBO CONTROLLED, THREE WAY CROSSOVER STUDY TO ASSESS THE BRONCHODILATOR EFFECT OF RPL554 ADMINISTERED IN ADDITION TO OPEN LABEL TIOTROPIUM/OLODATEROL IN PATIEN...||2018-11-13||due-trials|
|Ongoing||2020-002069-32||A Phase III Randomized, Double-Blind, Placebo- Controlled Study to Evaluate the Efficacy and Safety of Ensifentrine over 24 Weeks in Patients with Moderate to Severe Chronic Obstructive Pulmonary Dise...||not-yet-due|
|Ongoing||2020-002086-34||A Phase III Randomized, Double-Blind, Placebo- Controlled Study to Evaluate the Efficacy and Safety of Ensifentrine over 24 Weeks (With a 48-Week Safety Subset) in Patients with Moderate to Severe Chr...||not-yet-due|